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Background
Severe asthma are linked with high morbidity, significant
mortality and high treatment costs. Omalizumab has
been shown to decrease the risk of hospitalization or
Emergency Department (ED) visits in patients with
uncontrolled severe allergic asthma. We aim to describe
the conditions under Omalizumab was prescribed in
patients followed in a Reference Center for Severe
Asthma Treatment in Nova Iguaçu, Rio de Janeiro; and
assess the effects of Omalizumab through the Asthma
Control Test (ACT) in those patients who had at least a
16 week course.
Methods
Asthmatic patients treated with omalizumab between
February 2013 and June 2014 were evaluated retrospec-
tively. The conditions under Omalizumab was prescribed
and ACT improvements were evaluated.
Results
A total of 19 patients (14 females and 5 males) were
prescribed omalizumab. Prescribing criteria were: one or
more ED visits in the last year (100%); high dose inhaled
corticosteroid and long-acting beta2agonist use (94.7%);
systemic corticosteroid use more than 3 times the last
year (89.5%); FEV<80% (78.9%); daily short-acting
beta2agonist use (68.4%); fast pulmonary function dete-
rioration after systemic corticosteroid withdrawal
(52.6%); death threatening asthma exacerbation episode
(42%). Seven of these patients had a 16 week course of
omalizumab with a significant improvement in ACT
total score in six of them (86%).
Conclusions
In our casuistic, the main criteria omalizumab was pre-
scribed for severe asthma was ED visits. Omalizumab
promoted a significant improvement in most patients’
ACT total score.
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